<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="126208">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02092974</url>
  </required_header>
  <id_info>
    <org_study_id>LESO</org_study_id>
    <nct_id>NCT02092974</nct_id>
  </id_info>
  <brief_title>Mechanism of tDCS-induced Learning Enhancement - the Role of Serotonin</brief_title>
  <acronym>LESO</acronym>
  <official_title>Mechanism of tDCS-induced Learning Enhancement - the Role of Serotonin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to assess whether the application of a selective serotonin reuptake
      inhibitor (SSRI) enhances and prolongs the learning enhancement achieved by anodal
      transcranial direct current stimulation (atDCS). For this, young and older healthy subjects
      will be tested with a well established learning paradigm. Results of this study may help to
      support the application of atDCS also in patients, e.g. with dementia or mild cognitive
      impairment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Recall score after learning under tDC stimulation + SSRI compared to learning under tDC stimulation + placebo.</measure>
    <time_frame>immediately after end of learning phase (approx. 1 hour)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Recall score immediately after learning phase (=training of visual-spatial abilities) under tDC stimulation + SSRI application compared to learning under tDC stimulation + placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>prolongation of the atDCS induced learning enhancement by SSRI</measure>
    <time_frame>1 week</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measurement of recall scores on the evening of the same day after the learning phase (+tDCS + SSRI), the morning of the day after and 1 week later in order to assess the prolongation of atDCS induced learning enhancement by the SSRI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Increase of learning enhancement by atDCS + placebo or sham-tDCS + SSRI vs. sham-tDCS + placebo</measure>
    <time_frame>immediately after learning phase (approx. 1 hour)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measurement of recall scores directly after learning phase after application of atDCS + placebo or sham-tDCS + SSRI vs. sham-tDCS + placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>prolongation of learning enhancement by atDCS + placebo or sham-tDCS + SSRI vs. sham-tDCS + placebo</measure>
    <time_frame>1 week</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measurement of recall scores on the evening of the same day of learning phase, the morning of the day after and 1 week later under application of atDCS + placebo or sham-tDCS + SSRI vs. sham-tDCS + placebo, in order to assess prolongation of learning enhancement by SSRI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>genotyping of learning related polymorphisms</measure>
    <time_frame>once</time_frame>
    <safety_issue>No</safety_issue>
    <description>To assess predictors of SSRI-enhanced brain stimulation, genotyping of several learning related polymorphisms will be performed (i.e., APOE, BDNF, Val66Met, COMT, Val158Met, KIBRA, rs17070145, 5-Hydroxytryptamine transporter).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Healthy Young and Older Adults</condition>
  <arm_group>
    <arm_group_label>tDCS + SSRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>tDCS + placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>sham-tDCS + SSRI</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>sham-DCS + placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>tDCS</intervention_name>
    <arm_group_label>tDCS + SSRI</arm_group_label>
    <arm_group_label>tDCS + placebo</arm_group_label>
    <other_name>transcranial direct current stimulation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Citalopram</intervention_name>
    <arm_group_label>tDCS + SSRI</arm_group_label>
    <arm_group_label>sham-tDCS + SSRI</arm_group_label>
    <other_name>SSRI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  right handedness

          -  unobtrusive neuropsychological screening

          -  ability to provide written informed consent

          -  no pathological findings in head MRI

          -  age: 18 to 35 years (young adults) or 50-80 years (older adults)

          -  Highly effective contraception (Pearl Index &lt; 1) or reliable abstinence from any
             heterosexual relationships in women of childbearing potential

        Exclusion Criteria:

          -  severe internal or psychiatric disease (especially depression or suicidal thoughts)

          -  epilepsy

          -  cognitive impairment (&lt; SD under age adjusted norm in neuropsychological testing)

          -  concurrent taking of serotonin precursors (tryptophan, 5-HTP) or MAO inhibitors

          -  concurrent taking of tramadol or triptans

          -  concurrent taking of pimozide or linezolid

          -  concurrent taking of other drugs prolonging the QT-interval

          -  long-QT-syndrome

          -  hypokalemia or hypomagnesemia

          -  known intolerance of the study medication

          -  claustrophobia or metallic implants, tattoos (MRI exclusion criteria)

          -  pregnancy or lactation

          -  participation in another drug-interventional clinical trial within the last month or
             during the entire study

          -  probands that are placed in an institution due to official or judicial order

          -  non-agreement to save and transmit pseudonymised study data within the clinical trial
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Agnes Flöel, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite University, Berlin, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Agnes Flöel, Prof. Dr.</last_name>
    <phone>0049 30 450 560284</phone>
    <email>agnes.floeel@charite.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kristin Prehn, Dr.</last_name>
    <phone>0049 30 450 560140</phone>
    <email>kristin.prehn@charite.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Charite Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agnes Flöel, Prof. Dr.</last_name>
      <phone>0049 30 450560284</phone>
      <email>agnes.floeel@charite.de</email>
    </contact>
    <contact_backup>
      <last_name>Kristin Prehn, Dr.</last_name>
      <phone>0049 30 450560140</phone>
      <email>kristin.prehn@charite.de</email>
    </contact_backup>
    <investigator>
      <last_name>Agnes Flöel, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 16, 2014</lastchanged_date>
  <firstreceived_date>March 19, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Agnes Flöel</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <keyword>transcranial direct current stimulation (tDCS)</keyword>
  <keyword>selective serotonin reuptake inhibitor (SSRI)</keyword>
  <keyword>young</keyword>
  <keyword>older adults</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Serotonin Uptake Inhibitors</mesh_term>
    <mesh_term>Dexetimide</mesh_term>
    <mesh_term>Serotonin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
